Amgen Inc. is bolstering its immuno-oncology franchise and making its first foray into the hot chimeric antigen receptor (CAR) T-cell therapy field through an early stage deal with Kite Pharma Inc. that, if successful, could prove lucrative for both firms. Read More
HONG KONG – Chinese pharmaceutical regulators will begin 2015 by taking aim at improving supervision of shelf-life studies and storage of biological products in order to enhance consumer safety. Read More
Tallying venture capital investments aplenty last year, Aduro Biotech Inc. chalked up more in a series D preferred stock financing of $51.4 million for its immuno-oncology pipeline, an amount that brings the total haul for the Berkeley, Calif.-based firm in 2014 to $106.4 million. Read More
The search for ways to increase life span is based on the idea that such an increased life span will extend the good parts of life – meaning, by and large, the healthy parts. Read More
Seemingly confident in the level of similarity between Sandoz Inc.'s Zarxio and Amgen Inc.'s Neupogen, the FDA has one voting question for the Oncologic Drugs Advisory Committee (ODAC) that will weigh in Wednesday on what is likely to be the first U.S. biosimilar. Read More
There's nothing like starting the new year on a high note with news of a record venture financing. Cambridge, Mass.-based Moderna Therapeutics Inc. said it closed a whopping $450 million financing that will fuel and expand its messenger RNA (mRNA) therapeutics platform across a number of therapeutic indications. Read More
Clementia Pharmaceuticals Inc., of Montreal, said it secured an additional $10 million from its current investors to support development of their lead compound palovarotene for the treatment of fibrodysplasia ossificans progressive (FOP). Read More
Biomedx GmbH, of Heidelberg, Germany, said it entered a collaboration agreement with Boehringer Ingelheim GmbH, of Ingelheim, Germany, to establish a research group focusing on the identification of therapeutic concepts for treating patients with chronic obstructive pulmonary disease (COPD). Read More
Cel-Sci Corp. shares (NYSE:CVM) rose 7 cents, or 11.3 percent, to 69 cents Monday, as the company reported that in 2014 it enrolled almost 200 patients with advanced primary, untreated head and neck cancer into its global pivotal phase III head and neck cancer trial for its investigational immunotherapy Multikine (leukocyte interleukin). Read More
Bristol-Myers Squibb Co., of New York, the California Institute for Biomedical Research (Calibr) entered into a worldwide research collaboration to develop small-molecule anti-fibrotic therapies, and an exclusive license agreement that allows Bristol-Myers Squibb to develop, manufacture and commercialize Calibr's preclinical compounds resulting from the collaboration. Read More
Fennec Pharmaceuticals Inc., of Research Triangle Park, N.C., said the second sodium thiosulfate (STS) phase III study, SIOPEL 6, has fully enrolled and is now closed for recruitment. Read More
The National Institutes of Health (NIH) is seeking comments on its draft policy promoting the use of a single institutional review board (IRB) for all domestic sites in multisite studies funded by the institutes. Read More
